Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease

Shares of Novo Nordisk climbed almost 5% Monday after the company’s blockbuster Wegovy obesity drug received accelerated approval from the U.S. Food and Drug Administration to treat a serious liver disease.

The company on Friday said that it was granted the approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, in combination with a reduced calorie diet and increased physical activity.

Novo Nordisk shares were up 5.05% by 9:59 a.m. London time (4:45 a.m. E.T.).

This is a developing story. Please check back for updates.